These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 34871862)

  • 21. ZEB1 mediates doxorubicin (Dox) resistance and mesenchymal characteristics of hepatocarcinoma cells.
    Long L; Xiang H; Liu J; Zhang Z; Sun L
    Exp Mol Pathol; 2019 Feb; 106():116-122. PubMed ID: 30615851
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The deoxycholic acid targets miRNA-dependent CAC1 gene expression in multidrug resistance of human colorectal cancer.
    Kong Y; Bai PS; Sun H; Nan KJ; Chen NZ; Qi XG
    Int J Biochem Cell Biol; 2012 Dec; 44(12):2321-32. PubMed ID: 22903020
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination treatment with doxorubicin and microRNA-21 inhibitor synergistically augments anticancer activity through upregulation of tumor suppressing genes.
    Zhang S; Han L; Wei J; Shi Z; Pu P; Zhang J; Yuan X; Kang C
    Int J Oncol; 2015 Apr; 46(4):1589-600. PubMed ID: 25625875
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MiR-375 delivered by lipid-coated doxorubicin-calcium carbonate nanoparticles overcomes chemoresistance in hepatocellular carcinoma.
    Zhao P; Wu S; Cheng Y; You J; Chen Y; Li M; He C; Zhang X; Yang T; Lu Y; Lee RJ; He X; Xiang G
    Nanomedicine; 2017 Nov; 13(8):2507-2516. PubMed ID: 28577837
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin.
    Kim TH; Shin YJ; Won AJ; Lee BM; Choi WS; Jung JH; Chung HY; Kim HS
    Biochim Biophys Acta; 2014 Jan; 1840(1):615-25. PubMed ID: 24161697
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Delivery of miR-375 and doxorubicin hydrochloride by lipid-coated hollow mesoporous silica nanoparticles to overcome multiple drug resistance in hepatocellular carcinoma.
    Xue H; Yu Z; Liu Y; Yuan W; Yang T; You J; He X; Lee RJ; Li L; Xu C
    Int J Nanomedicine; 2017; 12():5271-5287. PubMed ID: 28769563
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MicroRNA-520c-3p Modulates Doxorubicin-Chemosensitivity in HepG2 Cells.
    Ragheb MA; Soliman MH; Elzayat EM; Mohamed MS; El-Ekiaby N; Abdelaziz AI; Abdel-Wahab AA
    Anticancer Agents Med Chem; 2021; 21(2):237-245. PubMed ID: 32357822
    [TBL] [Abstract][Full Text] [Related]  

  • 28. miR-140-5p inhibits the proliferation and enhances the efficacy of doxorubicin to breast cancer stem cells by targeting Wnt1.
    Wu D; Zhang J; Lu Y; Bo S; Li L; Wang L; Zhang Q; Mao J
    Cancer Gene Ther; 2019 Mar; 26(3-4):74-82. PubMed ID: 30032164
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Wild type p53 sensitizes soft tissue sarcoma cells to doxorubicin by down-regulating multidrug resistance-1 expression.
    Zhan M; Yu D; Lang A; Li L; Pollock RE
    Cancer; 2001 Sep; 92(6):1556-66. PubMed ID: 11745235
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recombinant Methioninase Is Selectively Synergistic With Doxorubicin Against Wild-type Fibrosarcoma Cells Compared to Normal Cells and Overcomes Highly-Doxorubicin-resistant Fibrosarcoma.
    Morinaga S; Han Q; Mizuta K; Kang BM; Sato M; Bouvet M; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Higuchi T; Tsuchiya H; Demura S; Hoffman RM
    Anticancer Res; 2024 Aug; 44(8):3261-3268. PubMed ID: 39060039
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Knockdown of Long Non-Coding RNA XIST Inhibited Doxorubicin Resistance in Colorectal Cancer by Upregulation of miR-124 and Downregulation of SGK1.
    Zhu J; Zhang R; Yang D; Li J; Yan X; Jin K; Li W; Liu X; Zhao J; Shang W; Yu T
    Cell Physiol Biochem; 2018; 51(1):113-128. PubMed ID: 30439718
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Doxorubicin induces expression of multidrug resistance-associated protein 1 in human small cell lung cancer cell lines by the c-jun N-terminal kinase pathway.
    Shinoda C; Maruyama M; Fujishita T; Dohkan J; Oda H; Shinoda K; Yamada T; Miyabayashi K; Hayashi R; Kawagishi Y; Fujita T; Matsui S; Sugiyama E; Muraguchi A; Kobayashi M
    Int J Cancer; 2005 Oct; 117(1):21-31. PubMed ID: 15880572
    [TBL] [Abstract][Full Text] [Related]  

  • 33. LncRNA MALAT1 mediates doxorubicin resistance of hepatocellular carcinoma by regulating miR-3129-5p/Nova1 axis.
    Cao Y; Zhang F; Wang H; Bi C; Cui J; Liu F; Pan H
    Mol Cell Biochem; 2021 Jan; 476(1):279-292. PubMed ID: 32965597
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MicroRNA-383 inhibits doxorubicin resistance in hepatocellular carcinoma by targeting eukaryotic translation initiation factor 5A2.
    Tu C; Chen W; Wang S; Tan W; Guo J; Shao C; Wang W
    J Cell Mol Med; 2019 Nov; 23(11):7190-7199. PubMed ID: 30801960
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of cyclin D1 overexpression on drug sensitivity in a human fibrosarcoma cell line.
    Hochhauser D; Schnieders B; Ercikan-Abali E; Gorlick R; Muise-Helmericks R; Li WW; Fan J; Banerjee D; Bertino JR
    J Natl Cancer Inst; 1996 Sep; 88(18):1269-75. PubMed ID: 8797766
    [TBL] [Abstract][Full Text] [Related]  

  • 36. LncRNA LOXL1-AS1/miR-let-7a-5p/EGFR-related pathway regulates the doxorubicin resistance of prostate cancer DU-145 cells.
    Bai T; Liu Y; Li B
    IUBMB Life; 2019 Oct; 71(10):1537-1551. PubMed ID: 31188543
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Restoration of microRNA-197 expression suppresses oncogenicity in fibrosarcoma through negative regulation of RAN.
    Jain N; Das B; Mallick B
    IUBMB Life; 2020 May; 72(5):1034-1044. PubMed ID: 32027089
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MiR-202-5p/
    Liu T; Guo J; Zhang X
    Cancer Biol Ther; 2019; 20(7):989-998. PubMed ID: 30983514
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MicroRNA-34 mediates AR-dependent p53-induced apoptosis in prostate cancer.
    Rokhlin OW; Scheinker VS; Taghiyev AF; Bumcrot D; Glover RA; Cohen MB
    Cancer Biol Ther; 2008 Aug; 7(8):1288-96. PubMed ID: 18497571
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MiR-451a attenuates doxorubicin resistance in lung cancer via suppressing epithelialmesenchymal transition (EMT) through targeting c-Myc.
    Tao L; Shu-Ling W; Jing-Bo H; Ying Z; Rong H; Xiang-Qun L; Wen-Jie C; Lin-Fu Z
    Biomed Pharmacother; 2020 May; 125():109962. PubMed ID: 32106373
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.